Peptides News and Research

RSS

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer’s disease (AD).

24 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Two UCSF scientists selected for Potamkin Prize for their achievements in research on dementias

Two UCSF scientists have been selected for the American Academy of Neurology's prestigious Potamkin Prize, for their "outstanding achievements" in research on dementias.

19 Feb 2010

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lennart Mucke, MD, Director of the Gladstone Institute of Neurological Disease (GIND), has been named a recipient of the American Academy of Neurology's prestigious Potamkin Prize.

19 Feb 2010

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

Biotage announces global launch of Syro Wave microwave and parallel peptide synthesizer

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave™; their new microwave and parallel peptide synthesizer. The Syro Wave™ is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.

18 Feb 2010

Research opens up new exploration possibilities for Alzheimer's disease

Researchers at Universitat Aut-noma de Barcelona (UAB) and University of Stockholm have created a computer modelling of the structural malfunctioning of the ApoE4 protein when it enters into contact with the Amyloid beta molecule, the main cause of Alzheimer's disease.

18 Feb 2010

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

17 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Directing gold nanoparticles into nucleus can kill cancer cells

Taking gold nanoparticles to the cancer cell and hitting them with a laser has been shown to be a promising tool in fighting cancer, but what about cancers that occur in places where a laser light can't reach? Scientists at the Georgia Institute of Technology have shown that by directing gold nanoparticles into the nuclei of cancer cells, they can not only prevent them from multiplying, but can kill them where they lurk. The research appeared as a communication in the February 10 edition of the Journal of the American Chemical Society.

17 Feb 2010

Research suggests scorpion venom could be an alternative to morphine painkiller

Scorpion venom is notoriously poisonous ― but it might be used as an alternative to dangerous and addictive painkillers like morphine, a Tel Aviv University researcher claims.

17 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

Researchers have traced protein that stops cells from becoming cancerous

In the dominoes that make up human cells, researchers at the University of Michigan Comprehensive Cancer Center have traced another step of the process that stops cells from becoming cancerous.

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.

16 Feb 2010

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

AB SCIEX, a global leader in life science analytical technologies, today announced that it has acquired the liquid chromatography business of Eksigent Technologies. This acquisition significantly strengthens AB SCIEX’s position in liquid chromatography, which is a key technology used frequently in a broad range of life science applications such as protein biomarker research, drug discovery and basic research.

16 Feb 2010

Isogenica enters into agreement with Dstl to develop antimicrobial peptide drugs

Isogenica Ltd today announced that it has entered into an agreement with UK Ministry of Defence agency, the Defence Science and Technology Laboratory. The agreement concerns the development of antimicrobial peptide drugs and follows a successful collaboration to identify highly effective antimicrobial peptides which are active against a broad spectrum of bacteria.

15 Feb 2010

Calcium waves could be relevant for understanding the origin of Alzheimer's disease

New insights on what causes Alzheimer's disease could arise from a recent discovery made by bioengineers from the University of California, San Diego. The finding concerns the infamous amyloid beta peptides (Aβ)-fragments of which form plaques thought to play a role in Alzheimer's disease.

15 Feb 2010

Peptides News and Research

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

New treatments for heart disease

Study shows CEL-2000 vaccine blocks RA progression in mice

Two UCSF scientists selected for Potamkin Prize for their achievements in research on dementias

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lower dose of avosentan drug may provide more favorable results in diabetes patients

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Biotage announces global launch of Syro Wave microwave and parallel peptide synthesizer

Research opens up new exploration possibilities for Alzheimer's disease

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Directing gold nanoparticles into nucleus can kill cancer cells

Research suggests scorpion venom could be an alternative to morphine painkiller

Researchers use new strategy to develop cancer vaccines

Researchers have traced protein that stops cells from becoming cancerous

New fluorescent probes improve tumor detection in mice

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

Isogenica enters into agreement with Dstl to develop antimicrobial peptide drugs

Calcium waves could be relevant for understanding the origin of Alzheimer's disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News